Transforming Advanced Lung Cancer Into a Chronic Disease: Answering Key Questions - priME Oncology
Webcast
Webcast

Transforming Advanced Lung Cancer Into a Chronic Disease: Answering Key Questions

Not a member of My prIME? Join now for instant access.

Transforming Advanced Lung Cancer Into a Chronic Disease: Answering Key Questions

View Webcast

Activity Overview

This CME-certified Webcast contains video and downloadable slides from the symposium Transforming Advanced Lung Cancer Into a Chronic Disease: Answering Key Question’s, a prIME Oncology educational activity that was held on Monday, September 7, 2015, in Denver, in conjunction with the 16th World Conference on Lung Cancer.

Topics

Is non-small cell lung cancer (NSCLC) becoming a chronic disease?
Paul A. Bunn, Jr, MD

What are the best strategies to overcome acquired tyrosine kinase inhibitor resistance?
Suresh Ramalingam, MD

When should an immunotherapeutic approach be considered in NSCLC management?
Joel Neal, MD, PhD

  • Paul A. Bunn, Jr, MDUniversity of Colorado Denver
    Denver, Colorado, United States
  • Joel Neal, MD, PhDStanford Comprehensive Cancer Center
    Stanford, California, United States
  • Suresh Ramalingam, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States

Target Audience

This activity is designed to meet the needs of medical oncologists, surgical and radiation oncologists, pulmonologists, pathologists, and other healthcare professionals involved in the treatment of patients with NSCLC.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Discuss the mechanisms of acquired resistance to tyrosine kinase inhibitors (TKIs) in NSCLC
  • Explain emerging strategies to overcome resistance to TKIs in the treatment of NSCLC
  • Discuss emerging data on treatment agents and immunotherapeutic approaches for NSCLC, including oncogenic signaling inhibitors
View Webcast

Provider

This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
ACCME
prIME Oncology designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This educational activity is supported by a grant from AstraZeneca.

Activity Date

RELEASE DATE
October 30, 2015

EXPIRATION DATE
October 30, 2016